Mr. Speaker, I thank the hon. member for his question which was originally directed to the Minister of Health. I congratulate the member on raising these issues. I know it is important to him and obviously important to others, including myself in this House.
Clearly, many departments are involved in this dealing with stakeholders and particularly the ministry of health. As the hon. member knows, extensive detail on the activity which he raises has been a priority.
Health Canada is engaged in a careful assessment and analysis of the options to address possible risk to the drug supply, particularly the issue of prices. As the minister has made clear, the issue will soon be discussed in cabinet. I give that assurance to the member. We continue to monitor the situation south of the border. As the member knows, there has been increased demand by Americans.
Current levels of cross-border drug sales are a small fraction of the total U.S. market. There are millions of Americans who have no health coverage at all, no adequate health insurance at all. Clearly, cross-border drug sales from Canada are not a sustainable solution to the potential needs of those people.